These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 36092543)

  • 21. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].
    Bocher V; Chinetti G; Fruchart JC; Staels B
    J Soc Biol; 2002; 196(1):47-52. PubMed ID: 12134632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy].
    Bełtowski J; Wójcicka G; Jamroz A
    Postepy Hig Med Dosw; 2003; 57(2):199-217. PubMed ID: 12866356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PPAR Ligands Containing Stilbene Scaffold.
    Fantacuzzi M; De Filippis B; Amoroso R; Giampietro L
    Mini Rev Med Chem; 2019; 19(19):1599-1610. PubMed ID: 31161987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.
    Kapadia R; Yi JH; Vemuganti R
    Front Biosci; 2008 Jan; 13():1813-26. PubMed ID: 17981670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD; Plutzky J
    Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The role of peroxisome proliferator-activated receptors (PPAR) in carcinogenesis].
    Knapp P; Jarzabek K; Błachnio A; Zbroch T
    Ginekol Pol; 2006 Aug; 77(8):643-51. PubMed ID: 17076197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic and additional vascular effects of thiazolidinediones.
    Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
    Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dietary regulation of peroxisome proliferator-activated receptors in metabolic syndrome.
    Zou H; Gong Y; Ye H; Yuan C; Li T; Zhang J; Ren L
    Phytomedicine; 2023 Jul; 116():154904. PubMed ID: 37267691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview on biological mechanisms of PPARs.
    Kota BP; Huang TH; Roufogalis BD
    Pharmacol Res; 2005 Feb; 51(2):85-94. PubMed ID: 15629253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.
    Wagner N; Wagner KD
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [PPAR family and its relationship to metabolic syndrome].
    Zhang XY; Chen LH; Guan YF
    Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):6-12. PubMed ID: 15881336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.
    Ivanova EA; Myasoedova VA; Melnichenko AA; Orekhov AN
    Curr Pharm Des; 2017; 23(7):1119-1124. PubMed ID: 27855608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.
    Grommes C; Landreth GE; Heneka MT
    Lancet Oncol; 2004 Jul; 5(7):419-29. PubMed ID: 15231248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peroxisome proliferator-activated receptor (PPAR) agonists as a potential therapy for inherited metabolic disorders.
    Seminotti B; Grings M; Glänzel NM; Vockley J; Leipnitz G
    Biochem Pharmacol; 2023 Mar; 209():115433. PubMed ID: 36709926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.